87% (n ¼ 26) of the studies reported aneurysm rupture, 70% (n ¼ 21) of the studies reported aneurysm-related death, 70% (n ¼ 21) of the studies reported primary or secondary technical success, 50% (n ¼ 15) of the studies reported clinical success or clinical failure, and 73% (n ¼ 22) of the studies reported longitudinal outcomes. Adherence to the SVS reporting guidelines for EVARs was 17% (n ¼ 5) for aneurysm rupture, 40% (n ¼ 12) for aneurysm-related death, 27% (n ¼ 8) for primary or secondary technical success, 20% (n ¼ 6) for clinical success or clinical failure, and 10% (n ¼ 3) for longitudinal outcomes. The Table further stratifies adherence rates to the SVS reporting guidelines by RCT and MCS.
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Modified Frailty Index to Predict Adverse Outcomes and Mortality in Open Surgical Repair of a Ruptured Abdominal Aortic Aneurysm
Objective: In recent years, there has been more interest in frailty in the surgical patient and its implication for outcomes. A simplified form of the original frailty index from the Canadian Study of Health and Aging has been established as the modified frailty index (mFI) and has been used as a predictor of morbidity and mortality after surgery. In our study, we have sought to apply the mFI to open surgical repair of a ruptured abdominal aortic aneurysm.
Methods: The 2010 American College of Surgeons National Surgical Quality Improvement Program database was used; patients undergoing open surgical repair of a ruptured abdominal aortic aneurysm were identified. We applied an mFI with 11 variables based on the Canadian Study of Health and Aging frailty index to the National Surgical Quality Improvement Program comorbidities. A bivariate analysis was done using logistic regression analysis. Factors associated with increased risk of mortality were identified.
Results: A total of 258 patients (79% male, 21% female; mean age, 72.9 years; mean body mass index, 27.8; 91.8% white, 7.3% African American, 0.5% Asian, 0.5% Native Hawaiian or Pacific Islander) underwent an open surgical repair of a ruptured abdominal aortic aneurysm. Incidence of 30-day mortality was 29% (for mFI <0.27) vs 46% (for mFI 0.27); postoperative myocardial infarct, 9% (for mFI <0.27) vs 8% (for mFI 0.27); stroke, 1.6% (for mFI <0.27) vs 4.8% (for mFI 0.27); postoperative progressive renal failure, 1.6% (for mFI <0.27) vs 4.8% (for mFI 0.27); and postoperative return to the operating room, 15.8% (for mFI <0.27) vs 15.9% (for mFI 0.27).
Conclusions: This study demonstrates that the mFI can be used as a valuable tool to identify patients at a higher risk for postoperative morbidity and mortality after open surgical repair of a ruptured abdominal aortic aneurysm. The study has also shown that for an mFI of 0.27, the risk of mortality and complications increases significantly. The mFI can be used as a screening tool to identify patients who are at a high risk for development of complications. Objective: Repair of aortic disease extending proximal to the left subclavian artery is challenging with few durable options. With the advent of new endovascular devices to treat aortic arch conditions, a historical comparison is required for evaluation of efficacy and safety.
Methods: A review was conducted of 19 consecutive descending aortic repairs with thoracic endovascular aortic repair (TEVAR) and left common carotid artery chimney grafts at a single institution between January 1,2011, and September 30, 2016.
Results: Indication for repair included chronic aneurysm in seven (37%), aneurysmal degeneration after type B dissection in six (31.5%), transection related to blunt trauma in two (10.5%), mycotic aneurysm in one (5%), anastomotic pseudoaneurysm with aortobronchial fistula in one (5%), pseudoaneurysm in the setting of radiation for cancer in one (5%), and large penetrating atherosclerotic ulcer in one (5%). Ten (52.6%) of the repairs were done electively. Nine (47.4%) were done urgently in the setting of chest pain (four), rupture (two), transection (two), and hemoptysis (one). Zone 2 disease was present in 79%; the remainder (21%) had zone 3 disease. All patients except one had left carotid sheath access before TEVAR deployment, which was performed as a rescue for an inadvertently covered left carotid. Subclavian or axillary revascularization was performed in all patients except those with trauma. Immediate technical success was observed in all patients. Two (10.5%) suffered right hemispheric strokes but recovered completely. There was one in-hospital death (5%) due to ruptured aneurysm in the setting of chronic type B dissection. Median length of stay was 9 days. Thirteen (68%) were discharged to home. Median follow-up was 738 days. The 2-year survival Type of study Aneurysm rupture, % Aneurysm-related death, % Technical success, % Clinical success or failure, % Longitudinal outcome, %
MCS, Multicenter cohort study; RCT, randomized clinical trial.
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June 2018 was 77%, during which four patients died of nonaortic disease. Reintervention rate at 2 years was 24% (Fig) . One patient had an open conversion for type IA endoleak, one patient has had continued aneurysmal growth during 6 years by non-contrast-enhanced imaging but has declined intervention, and one patient has a type IB leak but elected to complete a course of chemotherapy before repair. One patient had asymptomatic occlusion of the carotid stent.
Conclusions: Left common carotid artery chimney graft with TEVAR was an effective way to extend the proximal landing zone in this highrisk population. Aorta-specific mortality was rare but reintervention was common. These outcomes should serve as a benchmark for future aortic arch interventions. Objective: The application of surgeon-modified fenestrated endografts to high-risk and acute aortic disease is desirable because of the morbid nature of open repair; however, the feasibility of this is largely unknown. We sought to describe outcomes of surgeon-modified fenestrated endovascular aneurysm repair (sm-FEVAR) for acute and high-risk aortic disease in patients who were deemed poor surgical candidates.
Methods: We retrospectively queried institutional data for all patients treated with sm-FEVAR at our facility between 2009 and 2017. The sm-FEVAR was performed for clinical necessity, with the patient's consent, and in anticipation of a physician-sponsored investigational device exemption application (Q171179). Predictors of major complications were determined using either c 2 test or t-test. Survival, reinterventionfree survival, and branch patency were analyzed using the Kaplan-Meier methods.
Results: Thirty-seven patients (mean age, 72.0 6 8.0 years; 67.2% male; follow-up, 319 6 420 days) underwent sm-FEVAR for paravisceral aneurysm (n ¼ 13), thoracic aortic aneurysm (n ¼ 9), anastomotic pseudoaneurysm (n ¼ 7), type IA endoleak, status post EVAR (n ¼ 5), and chronic type B aortic dissection (n ¼ 3). Average maximum diameter was 67.5 6 21.0 mm. Fifteen patients (40.5%) were symptomatic; one patient was ruptured. There were 104 branches total (mean, 2.8 6 1.2; celiac, 22; superior mesenteric artery, 32; renal, 50). Major complications occurred in 32% of patients (30-day mortality, 10.8%; spinal cord ischemia, 18.9%; newonset dialysis, 8.1%; respiratory failure, 13.5%). Repair for thoracic aortic aneurysm was associated with spinal cord ischemia (odds ratio, 11.1; 95% confidence interval [CI], 1.49-82.4; P ¼ .01) and major complications (odds ratio, 5.54; 95% CI, 1.81-16.95; P < .01). One-year survival, reintervention-free survival, and branch patency were 88.6% (95% CI, 78.6%-99.8%), 59.0% (41.3%-84.3%), and 95.9% (90.3%-100%), respectively (Fig) . Endoleak was present in 39% of patients during follow-up.
Conclusions: In our early experience, perioperative morbidity for sm-FEVAR is significant; however, it is less than reported rates for open repair in such high-risk patients and can be used to treat a variety of aortic diseases. Further studies and experience are needed to improve perioperative outcomes, to reduce reinterventions, and to improve long-term durability.
Author Disclosures: W. Clouse: Nothing to disclose; M. F. Conrad: Nothing to disclose; C. DeCarlo: Nothing to disclose; R. Lancaster: Nothing to disclose; J. Mohebali: Nothing to disclose; V. I. Patel: Nothing to disclose. Methods: We performed a retrospective review of all patients who underwent FEVAR at our institution with the Zenith Fenestrated AAA Endovascular Graft (Cook Medical, Bloomington, Ind) from 2013 to 2018. Small, slow type I and type III endoleaks at the end of the index procedure were routinely observed. We identified patients with type I or type III endoleaks by review of the completion angiogram and subsequently characterized endoleak type and location.
Results: Of 49 patients who underwent FEVAR, 28 (57%) had evidence of a type I or type III endoleak after implantation of all devices. Eleven patients underwent further intervention at the index procedure, and three endoleaks resolved completely. Twenty-five patients (51%) had a type I or type III endoleak on completion angiography. We excluded three patients without postoperative imaging: two yet to complete initial postoperative computed tomography angiography or duplex ultrasound and one lost to follow-up after discharge. For the 22 remaining patients, mean age was 75.6 years; 77% were male, and 77% were white. Mean aneurysm diameter was 61 mm. There were 61 branch vessels (42 renal Type I (from large unstented right renal artery fenestration) 1 (5) a Exact location of endoleak origin could not be determined.
